Co-Authors
This is a "connection" page, showing publications co-authored by STEFAN OCTAVIAN CIUREA and KAI CAO.
Connection Strength
3.928
-
Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv. 2021 10 26; 5(20):4031-4043.
Score: 0.842
-
Reply to: Use of Single-Antigen Flow Beads Assays to Assess Anti-HLA Donor-Specific Antibody Strength. Biol Blood Marrow Transplant. 2016 Feb; 22(2):395-396.
Score: 0.558
-
Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer. 2023 04 15; 129(8):1205-1216.
Score: 0.230
-
Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol. 2022; 13:1033871.
Score: 0.225
-
Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 01; 36(1):155-164.
Score: 0.207
-
Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Adv. 2020 08 11; 4(15):3474-3485.
Score: 0.194
-
Donor-specific anti-HLA antibodies and ?recipient-specific anti-HLA antibodies? The conundrum on pregnancy in transplantation. Am J Hematol. 2020 05; 95(5):E128-E130.
Score: 0.188
-
Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2019 May; 54(5):784.
Score: 0.177
-
Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv. 2018 09 11; 2(17):2254-2261.
Score: 0.170
-
The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2018 05; 53(5):521-534.
Score: 0.162
-
Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.
Score: 0.158
-
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017 10 19; 130(16):1857-1868.
Score: 0.158
-
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.
Score: 0.146
-
Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation. Adv Hematol. 2016; 2016:4025073.
Score: 0.141
-
Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1392-8.
Score: 0.135
-
SIRPa Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol. 2022; 13:904718.
Score: 0.055
-
Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica. 2022 04 01; 107(4):844-856.
Score: 0.054
-
Mismatch in SIRPa, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv. 2021 09 14; 5(17):3407-3417.
Score: 0.052
-
Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.
Score: 0.041
-
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant. 2016 07; 22(7):1290-1298.
Score: 0.036